# Faeth Therapeutics, Inc.: financial statements, quarterly

FTH · Nasdaq · CIK 1829802 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fth.md) · [Financials](/companies/fth/financials.md) · [Filings](/companies/fth/filings.md) · [Insiders](/companies/fth/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fth/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(7.7)](/filings/0000950170-24-126748.md) | [(8.1) d](/filings/0000950170-25-046338.md) | [(8.7)](/filings/0000950170-25-064525.md) | [(7.8)](/filings/0000950170-25-103101.md) | [(7.8)](/filings/0001193125-25-281590.md) | [(8.3) d](/filings/0001193125-26-132014.md) | [(7.3)](/filings/0001193125-26-225333.md) | [(5.2)](/filings/0001193125-26-331562.md) | [(4.9)](/filings/0001193125-25-281590.md) | [(5.0) d](/filings/0001193125-26-132014.md) | [(171)](/filings/0001193125-26-225333.md) | [(18.4)](/filings/0001193125-26-331562.md) |
| Interest expense | $m | [0.0](/filings/0000950170-24-126748.md) | [0.0 d](/filings/0000950170-25-046338.md) | [0.0](/filings/0000950170-25-064525.md) | [0.0](/filings/0000950170-25-103101.md) | [0.0](/filings/0001193125-25-281590.md) | [0.0 d](/filings/0001193125-26-132014.md) | [0.0](/filings/0000950170-25-064525.md) | [0.0](/filings/0000950170-25-103101.md) | [0.0](/filings/0001193125-25-281590.md) | [0.0 d](/filings/0001193125-26-132014.md) | not reported | not reported |
| Income tax | $m | [0.0 d](/filings/0000950170-24-126748.md) | not reported | [0.0](/filings/0000950170-25-064525.md) | [0.0 d](/filings/0000950170-25-103101.md) | [0.0 d](/filings/0001193125-25-281590.md) | [0.0 d](/filings/0001193125-26-132014.md) | [0.0](/filings/0001193125-26-225333.md) | [0.0](/filings/0001193125-26-331562.md) | [0.0 d](/filings/0001193125-25-281590.md) | [0.0 d](/filings/0001193125-26-132014.md) | [0.0](/filings/0001193125-26-225333.md) | [0.0](/filings/0001193125-26-331562.md) |
| Net income | $m | [(7.1)](/filings/0000950170-24-126748.md) | [(7.4) d](/filings/0000950170-25-046338.md) | [(8.0)](/filings/0001193125-25-281590.md) | [(7.1)](/filings/0001193125-25-281590.md) | [(7.3)](/filings/0001193125-25-281590.md) | [(7.8) d](/filings/0001193125-26-132014.md) | [(6.9)](/filings/0001193125-26-331562.md) | [(4.9)](/filings/0001193125-26-331562.md) | [(4.6)](/filings/0001193125-25-281590.md) | [(4.7) d](/filings/0001193125-26-132014.md) | [(170)](/filings/0001193125-26-331562.md) | [(16.0)](/filings/0001193125-26-331562.md) |
| Diluted EPS | $ per share | [(0.28)](/filings/0000950170-24-126748.md) | not reported | [(0.32)](/filings/0000950170-25-064525.md) | [(5.69)](/filings/0000950170-25-103101.md) | [(5.77)](/filings/0001193125-25-281590.md) | not reported | [(5.45)](/filings/0001193125-26-225333.md) | [(3.91)](/filings/0001193125-26-331562.md) | [(3.62)](/filings/0001193125-25-281590.md) | not reported | [(131.45)](/filings/0001193125-26-225333.md) | [(2.84)](/filings/0001193125-26-331562.md) |
| Basic EPS | $ per share | [(0.28)](/filings/0000950170-24-126748.md) | not reported | [(0.32)](/filings/0000950170-25-064525.md) | [(5.69)](/filings/0000950170-25-103101.md) | [(5.77)](/filings/0001193125-25-281590.md) | not reported | [(5.45)](/filings/0001193125-26-225333.md) | [(3.91)](/filings/0001193125-26-331562.md) | [(3.62)](/filings/0001193125-25-281590.md) | not reported | [(131.45)](/filings/0001193125-26-225333.md) | [(2.84)](/filings/0001193125-26-331562.md) |

- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.3](/filings/0000950170-23-060340.md) | [13.0](/filings/0000950170-25-046338.md) | [11.0](/filings/0000950170-24-057106.md) | [11.9](/filings/0000950170-24-091895.md) | [19.1](/filings/0000950170-24-126748.md) | [10.0](/filings/0001193125-26-132014.md) | [9.9](/filings/0000950170-25-064525.md) | [12.6](/filings/0000950170-25-103101.md) | [10.6](/filings/0001193125-25-281590.md) | [8.7](/filings/0001193125-26-331562.md) | [152](/filings/0001193125-26-225333.md) | [26.9](/filings/0001193125-26-331562.md) |
| Current assets | $m | [73.8](/filings/0000950170-23-060340.md) | [67.3](/filings/0000950170-25-046338.md) | [60.2](/filings/0000950170-24-057106.md) | [53.9](/filings/0000950170-24-091895.md) | [48.1](/filings/0000950170-24-126748.md) | [41.9](/filings/0001193125-26-132014.md) | [35.7](/filings/0000950170-25-064525.md) | [29.6](/filings/0000950170-25-103101.md) | [25.8](/filings/0001193125-25-281590.md) | [21.5](/filings/0001193125-26-331562.md) | [204](/filings/0001193125-26-225333.md) | [189](/filings/0001193125-26-331562.md) |
| Total assets | $m | [81.7](/filings/0000950170-23-060340.md) | [74.4](/filings/0000950170-25-046338.md) | [66.7](/filings/0000950170-24-057106.md) | [59.8](/filings/0000950170-24-091895.md) | [53.3](/filings/0000950170-24-126748.md) | [45.4](/filings/0001193125-26-132014.md) | [38.3](/filings/0000950170-25-064525.md) | [31.8](/filings/0000950170-25-103101.md) | [27.6](/filings/0001193125-25-281590.md) | [22.9](/filings/0001193125-26-331562.md) | [205](/filings/0001193125-26-225333.md) | [189](/filings/0001193125-26-331562.md) |
| Current liabilities | $m | [6.2](/filings/0000950170-23-060340.md) | [5.6](/filings/0000950170-25-046338.md) | [5.0](/filings/0000950170-24-057106.md) | [4.9](/filings/0000950170-24-091895.md) | [5.4](/filings/0000950170-24-126748.md) | [5.4](/filings/0001193125-26-132014.md) | [5.2](/filings/0000950170-25-064525.md) | [3.9](/filings/0000950170-25-103101.md) | [4.4](/filings/0001193125-25-281590.md) | [4.3](/filings/0001193125-26-331562.md) | [14.2](/filings/0001193125-26-225333.md) | [9.6](/filings/0001193125-26-331562.md) |
| Total liabilities | $m | [10.7](/filings/0000950170-23-060340.md) | [9.5](/filings/0000950170-25-046338.md) | [8.2](/filings/0000950170-24-057106.md) | [7.6](/filings/0000950170-24-091895.md) | [7.5](/filings/0000950170-24-126748.md) | [7.0](/filings/0001193125-26-132014.md) | [6.3](/filings/0000950170-25-064525.md) | [4.5](/filings/0000950170-25-103101.md) | [4.6](/filings/0001193125-25-281590.md) | [4.3](/filings/0001193125-26-331562.md) | [14.2](/filings/0001193125-26-225333.md) | [9.6](/filings/0001193125-26-331562.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [71.0](/filings/0000950170-24-126748.md) | [64.9](/filings/0001193125-26-132014.md) | [58.5](/filings/0001193125-25-281590.md) | [52.2](/filings/0001193125-25-281590.md) | [45.8](/filings/0001193125-25-281590.md) | [38.4](/filings/0001193125-26-331562.md) | [32.0](/filings/0001193125-26-331562.md) | [27.3](/filings/0001193125-26-331562.md) | [23.0](/filings/0001193125-25-281590.md) | [18.6](/filings/0001193125-26-331562.md) | [(137)](/filings/0001193125-26-331562.md) | [173](/filings/0001193125-26-331562.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(4.7) d](/filings/0000950170-24-126748.md) | [(6.2) d](/filings/0000950170-25-046338.md) | [(7.6)](/filings/0000950170-25-064525.md) | [(5.8) d](/filings/0000950170-25-103101.md) | [(5.5) d](/filings/0001193125-25-281590.md) | [(5.8) d](/filings/0001193125-26-132014.md) | [(7.1)](/filings/0001193125-26-225333.md) | [(5.9) d](/filings/0001193125-26-331562.md) | [(3.6) d](/filings/0001193125-25-281590.md) | [(3.9) d](/filings/0001193125-26-132014.md) | [(10.7)](/filings/0001193125-26-225333.md) | [(15.7) d](/filings/0001193125-26-331562.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-126748.md) | [0.0 d](/filings/0000950170-25-046338.md) | [0.0](/filings/0000950170-25-064525.md) | [0.1 d](/filings/0000950170-25-103101.md) | [0.0 d](/filings/0001193125-25-281590.md) | [0.0 d](/filings/0001193125-26-132014.md) | [0.0](/filings/0001193125-26-225333.md) | [0.0 d](/filings/0001193125-26-331562.md) | [0.0 d](/filings/0001193125-25-281590.md) | [0.0 d](/filings/0001193125-26-132014.md) | [0.0](/filings/0001193125-26-225333.md) | [0.0 d](/filings/0001193125-26-331562.md) |
| Share repurchases | $m | [2.3 d](/filings/0000950170-24-126748.md) | [0.3 d](/filings/0000950170-25-046338.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [30.7](/filings/0000950170-23-060340.md) | [30.9](/filings/0000950170-24-057106.md) | [30.5](/filings/0000950170-24-091895.md) | [25.5](/filings/0000950170-24-126748.md) | [25.0](/filings/0000950170-25-064525.md) | [1.3](/filings/0000950170-25-103101.md) | [1.3](/filings/0001193125-25-281590.md) | [1.3](/filings/0001193125-26-225333.md) | [1.3](/filings/0001193125-26-331562.md) | [1.3](/filings/0001193125-25-281590.md) | [1.3](/filings/0001193125-26-225333.md) | [5.6](/filings/0001193125-26-331562.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 25,840,425 at 2026-07-30, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-331562.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.